Novonesis reports over 29 Billion DKK turnover in 2024

Last year, Novonesis achieved a turnover of more than 3.9 billion euros, approximately 29.4 billion Danish kroner, which was an increase of 1.5 billion kroner from the previous year. The company, formed from the merger of Chr. Hansen and Novozymes, reported a profit of 276.6 million euros (about 2.063 billion kroner). Novonesis posted an organic growth rate of eight percent in sales, a measure excluding currency fluctuations and changes from acquisitions or divestitures. The two divisions, Food & Health Biosolutions and Planetary Health Biosolutions, recorded organic growth of seven and nine percent respectively. CEO Ester Baiget called 2024 an ‘excellent year’ with strong execution in sales and earnings. Looking ahead, Novonesis anticipates organic sales growth of five to eight percent for 2025, aligning with analysts’ projections. The company also announced a share buyback program of 100 million euros.